A veterinary review of the pharmacological basis and published clinical evidence supporting combined GS-441524 and EIDD-1931 therapy in the management of Feline Infectious Peritonitis (FIP).
Introduction
Feline Infectious Peritonitis (FIP), caused by virulent biotypes of feline coronavirus (FCoV), has transitioned from a uniformly fatal disease to a treatable condition since the introduction of the nucleoside analogue GS-441524 in 2019. Standard-of-care protocols using GS-441524 monotherapy at 4-10 mg/kg for 84 days have demonstrated consistently high remission rates across effusive, non-effusive, ocular, and neurological presentations.
However, as with all single-agent antiviral regimens, monotherapy carries inherent limitations: the potential for viral resistance under prolonged selective pressure, suboptimal CNS penetration in neurological cases, and incomplete viral clearance in a subset of treated patients. CURE FIP™ Dual Antiviral Oral Capsules address these limitations by combining GS-441524 and EIDD-1931 (β-D-N4-hydroxycytidine) in a single oral formulation.
Pharmacological Rationale
GS-441524: Chain Termination
GS-441524 is an adenosine nucleoside analogue that, following intracellular phosphorylation to its active triphosphate form (GS-443902), acts as a substrate for the viral RNA-dependent RNA polymerase (RdRp). The 1'-cyano substitution causes steric clash with the RdRp active site upon incorporation into the nascent RNA strand, resulting in delayed chain termination and cessation of viral RNA synthesis (Murphy et al., Veterinary Microbiology, 2018).
In vitro studies in CRFK cells demonstrated non-cytotoxicity at concentrations 100-fold above the effective dose for FIPV replication inhibition, indicating a wide therapeutic index. The plasma half-life of approximately 24 hours supports once-daily dosing.
EIDD-1931: Lethal Mutagenesis
EIDD-1931 (β-D-N4-hydroxycytidine, NHC) is the active metabolite of molnupiravir (EIDD-2801). Unlike chain-terminating nucleoside analogues, EIDD-1931 functions as a mutagenic ribonucleoside that incorporates into viral RNA without causing immediate chain termination. Instead, it serves as a template for misincorporation during subsequent replication rounds, alternating between cytidine and uridine base-pairing. This induces transition mutations (C-to-U and G-to-A) at increasing frequency until the cumulative mutation burden exceeds the error threshold, resulting in viral population collapse through error catastrophe.
Pharmacokinetic studies in cats with naturally occurring Feline Infectious Peritonitis (FIP) confirmed that oral EIDD-1931 achieves mean peak serum concentrations (Cmax) of approximately 1,551 ng/mL (~6 μM), with detectable levels sustained for at least 12 hours post-administration, supporting twice-daily dosing (Pathogens, 2025).
Synergistic Potential
The combination of a chain terminator (GS-441524) with a lethal mutagen (EIDD-1931) creates two simultaneous barriers to viral replication. GS-441524 directly reduces the output of new viral RNA copies. EIDD-1931 degrades the fidelity of remaining copies, rendering them progressively nonfunctional. This dual pressure reduces the effective viral population more rapidly than either agent alone and raises the genetic barrier to resistance.
Clinical Evidence
GS-441524 Monotherapy
Pedersen et al. (2019): Landmark field trial, UC Davis. 31 cats with naturally occurring Feline Infectious Peritonitis (FIP) (26 effusive, 5 non-effusive), GS-441524 2.0-4.0 mg/kg SC q24h, minimum 12 weeks. 24/26 completers in sustained remission. Fever resolution within 12-36 hours, effusion resolution in 10-14 days. J Feline Med Surg, 21(4):271-281
Coggins et al. (2023): Retrospective study, 307 cats with legally sourced remdesivir/GS-441524 (Australia, UK). 84.4% alive at longest follow-up (median 248 days). Relapse rate 10.8% (33/307). Cats achieving complete response within 30 days had significantly better survival. J Vet Intern Med
Krentz et al. (2024): Prospective RCT, LMU Munich. 40 cats with effusive Feline Infectious Peritonitis (FIP), 15 mg/kg PO q24h, 42 vs 84 days. 38/40 recovered with significant reduction in viral RNA loads. No significant difference between treatment durations. Pathogens
Delaplace et al. (2025): PRISMA systematic review. 11 studies, 650 cases. Overall success rate 84.6% (550/650). Higher with combination therapy. Effusive Feline Infectious Peritonitis (FIP) OR ~0.49 for success vs non-effusive. Neurological cases with combination therapy: GS+Remdesivir 10/10 survived, GS+GC376 7/8 survived. Pathogens
Molnupiravir/EIDD-1931
Kanai et al. (2023): First published case series. 18 cats (13 effusive, 5 non-effusive, 3 with neurological/ocular signs), molnupiravir 10-20 mg/kg PO q12h, 84 days. 14/14 completers in remission at 139-206 days follow-up. Transient ALT elevations in 3 cats (days 7-9). J Vet Intern Med
Kanai et al. (2024): Comparative study, 118 cats (76 effusive). 59 GS-441524, 59 molnupiravir. Mortality comparable: 12/59 (20.3%) GS group, 8/59 (13.6%) molnupiravir group (p=0.326). Remission among completers: GS 48/48, molnupiravir 51/52. Adverse events comparable between groups. Front Vet Sci
Roy et al. (2022): Rescue therapy documentation, Ohio State University. 26 cats post-GS failure. Mean starting dose 12.8 mg/kg, ending dose 14.7 mg/kg q12h, median 12 weeks. 24/26 disease-free. Notable AEs only at dosages >23 mg/kg q12h. Pathogens
Combination Antiviral Therapy in Feline Infectious Peritonitis (FIP)
Li et al. (2022): 46 cats with naturally acquired Feline Infectious Peritonitis (FIP) (36 wet, 10 dry). GS-441524 (2.5-5.0 mg/kg SC q24h) combined with GC376 (10-20 mg/kg SC q12h) for four weeks. 45/46 (97.8%) survived, 43 clinically normal at treatment end. All 45 survivors relapse-free at 10 months. Front Vet Sci
Clinical Considerations for Dual Therapy
Neurological Feline Infectious Peritonitis (FIP)
The most challenging presentation, with lower success rates even at escalated GS-441524 dosages (10-15 mg/kg). CSF penetration of GS-441524 is approximately 7-21% of plasma levels, varying between individual patients. The 2025 systematic review demonstrated that combination therapy significantly improved neurological Feline Infectious Peritonitis (FIP) outcomes compared to monotherapy. The addition of EIDD-1931 provides supplementary antiviral pressure that may compensate for suboptimal CNS drug levels.
Resistance Mitigation
Drug resistance to GS-441524 during prolonged monotherapy has been documented in the veterinary literature. The 84-day treatment duration creates sustained selective pressure favoring resistant viral variants. Dual-mechanism therapy raises the genetic barrier to resistance by requiring the virus to simultaneously acquire escape mutations against both chain termination and lethal mutagenesis.
Monitoring Recommendations
Standard monitoring protocols for GS-441524 monotherapy remain applicable during dual antiviral therapy. Clinicians should monitor: complete blood count with attention to neutrophil counts (given potential for transient neutropenia with EIDD-1931 at higher dosages), serum biochemistry with particular attention to ALT activity, body weight and clinical signs at regular intervals throughout the 84-day course, and post-treatment observation for a minimum of 12 weeks to monitor for relapse. Liver support supplementation should be considered throughout treatment.
Summary
The combination of GS-441524 and EIDD-1931 represents a pharmacologically rational evolution in Feline Infectious Peritonitis (FIP) treatment. By targeting viral replication through two orthogonal mechanisms (chain termination and lethal mutagenesis), dual therapy offers enhanced viral suppression, a higher genetic barrier to resistance, and potentially improved outcomes in challenging presentations such as neurological Feline Infectious Peritonitis (FIP).
The existing evidence base for each agent individually, combined with the strong evidence supporting combination antiviral strategies across virology, provides a compelling rationale for dual nucleoside analogue therapy in Feline Infectious Peritonitis (FIP) management.
For treatment protocols, dosage calculations, and clinical consultation, visit basmifip.com or contact the BasmiFIP veterinary support team via WhatsApp.
